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antiproliferative activity inducing p21 CIP1/WAF1 -mediated growth arrest and expression of differentiation markers (CD11b) in U937 cells (14, 21) . However, at higher concentrations (e.g., 5
μM), MS-275 potently induced cell death and a very early increase in death receptor signaling (22) as well as in reactive oxygen species (ROS), followed by the loss of mitochondrial membrane potential and cytosolic release of cytochrome c (23) .
The use of HDACi in combination with other anticancer agents (epi-drugs such as 5-aza-2′-deoxycytidine and retinoic acid) is one way forward to a promising application against cancer. In patients with leukemia, and particularly in the elderly, clinical studies combining ATRA treatment with HDACi are in progress (24) . For example, Valproic acid (VPA) has for many years been and still is used as an anti-epileptic drug and inhibits preferably class I HDACs although in the high micromolar to millimolar range. Moreover, even though there were a lot of concerns regarding toxic side effects of HDACi in the clinical setting due to the roles of HDACs in multiples pathways, until now clinical trials mostly showed manageable side effects (25) . The combination of ATRA with an
HDACi could result in improved anti-tumorigenic activity (24) .
Here, we exploited the synergy between HDACi and ATRA by generating and testing a single hybrid molecule, named MC2392 on APL cells. Genome-wide epigenetic analysis revealed that MC2392 is a weak retinoid. In contrast to the genome wide effects of MS-275 on histone H3 acetylation, MC2392 induces acetylation at only a small subset of PML-RARα binding sites in NB4 cells line. RNA-seq analysis showed that MC2392 alters the expression of a number of stressresponsive and apoptotic genes differently from ATRA. Importantly, the hybrid compound acts in a context and PML-RARα fusion protein-dependent fashion to induce rapid and massive cell death, RIP1 induction and ROS production. We propose a model in which this hybrid compound binds to the RARα via its retinoid-moiety and selectively inhibits the HDACs contained in the repressive complex via the MS-275 part. Taken together, MC2392 is a promising candidate for apoptosisbased therapy of APL, representing a new and effective, single hybrid drug able to modulate 6 Caspase 2 assay. Caspase-2 activity was detected within whole living cells, using Caspase-2
Fluorometric Kit following supplier's instructions (R&D). The plate was incubated at 37°C for 1h
and Fluorescence quantified with a TECAN M200 station at a 400-505 nm wavelength. Results are expressed as fold increase in caspase activity.
Analysis of mitochondrial membrane potential. Detection of the changes in mitochondrial membrane potential (ΔΨm) was performed using the MITOPT TM JC-1 kit (Immunochemistry Technologies) following the supplier's suggestions and analyzed by flow cytometry with Cell Quest Pro software.
ROS detection. NB4 cells were resuspended in pre-warmed PBS 1X, containing 5 μM of DCF-DA (diclorodihydrofluorescein diacetate) probe and incubated at 37°C for 20 minutes. Cells were analyzed after washing, using the Cell Quest software applied to a FACScalibur (BD). H 2 O 2 was used as positive control. 
RNA extraction, reverse transcription (RT) and quantitative PCR in real time (RT-PCR
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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performed using the H3K9K14ac (Diagenode), Nrf2, c-Fos and c-Jun (Santa Cruz) antibodies.
ChIPed DNA was analyzed by real time qPCR with specific primers (Biolegio, see Supplementary Methods) using the 2x SYBR Green mix (BIORAD) in a MyiQ thermocycler (BIORAD). Primers amplifying myoglobin were used as negative control. In addition, ChIPed DNA was prepared for sequencing and sequenced according to the manufacturer's instructions (Illumina) in Supplementary Materials and Methods and essentially as already described (32, 33) .
Peak Detection, Clustering analysis and Motif Search are detailed in the Supplementary
Materials and Methods.
RNA-sequencing. See Supplementary Materials and Methods.

Results
MC2392 inhibits HDAC activity of the PML-RARα complex and maintains retinoid activity.
We set out to exploit the possibility to combine the active parts of the HDACi MS-275 and the retinoid, ATRA, yielding MC2392 (Fig. 1A) . To explore the activities of this hybrid compound, U937 cells were treated for 24h with 5 μM MC2392, its parent compound MS-275 (Entinostat) a class I inhibitor and the class I/II HDAC inhibitor SAHA (Vorinostat). In contrast to the reference compounds, MC2392 did not result in a net increase of histone acetylation (Fig. 1B) . Moreover MC2392 did not induce p21 protein expression (Fig. 1B) corroborating that at this concentration the molecule has reduced or no HDACi activity as compared to MS-275. MC2392 exerted only minimal (if any) inhibitory action on HDAC1 and HDAC4, nor did it display SIRT1 modulating activities in vitro (Fig. 1C) . Our premise for the design of MC2392 was that the close physical proximity of a retinoid (PML-RARα) and an HDACi binding moiety (HDAC1 and/or -4) could convey context-specific inhibitory activity by a hybrid molecule spanning the physical distance. To investigate this assertion, PML-RARα was immunoprecipitated from HeLa cells after transient 8 transfection with PML-RARα and assayed for HDACi activity. Indeed, MC2392 inhibits the HDAC(s) resident in the PML-RARα repressive complex similarly to SAHA (Fig. 1D ).
To investigate whether MC2392 acts as a retinoid, its potential to activate the ATRA-responsive luciferase reporter (RARE 3 tkluc) was first tested in transient transfected HeLa that expresses endogenous RAR and RXR. MC2392 activates RARE 3 tkluc weakly compared to ATRA (Fig. 1E) .
Consistent with these observations, quantitative real-time PCR in NB4 cells showed a similar low response to MC2392 for the RNA expression of specific genes known to be retinoid modulated (34, 35) such as HOXA1, IRF1 and, to a lesser extent, TNFα, ( Supplementary Fig. 1A ) as compared to ATRA suggesting that MC2392 still maintains at least part of its retinoid activity. Finally, western blot analyses of PML-RARα following MC2392 treatment showed rapid degradation of PML-RARα in NB4 cells (Fig. 1F) as has been reported for ATRA (36, 37) . Taken together the results show that MC2392 acts as a weak retinoid when compared to ATRA implying that it binds to RARα, activates RARα signaling as well as induces the degradation of PML-RARα (Fig. 1F) . We tentatively conclude that MC2392 is an HDACi in the context of the PML-RARα-HDAC repressive complex.
MC2392 induces local H3 acetylation.
We showed that the HDACi activity of MC2392 is indeed apparent in the context of the PML-RARα-contained HDAC complexes implying that acetylation maybe altered at PML-RARα genomic binding sites. To examine whether MC2392 induces local epigenetic alterations, ChIP-seq profiling was performed using the H3K9K14ac antibody in NB4 cells treated with ATRA, MS-275, MC2392 or solvent, DMSO. In DMSO treated cells, H3K9K14 acetylation appeared in the typical sharp narrow peaks. Treatment with the HDACi MS-275 had a dramatic effect on the genomic acetylation landscape: H3K9K14ac peaks were dampened and spreading of acetylation occurred ( Fig. 2A) . In line with the absence of global HDACi activity (Fig. 1B) (Fig. 2C) . The RARβ is avidly transcriptionally induced by ATRA and expectedly H3 acetylation is induced at promoter region. These data suggest specificity and selectivity of MC2392 towards at least some PML-RARα binding sites and reinforced the similar, although weaker, retinoid activity of MC2392 as compared to ATRA (Fig. 1E, Supplementary Fig. 1A ).
To substantiate our findings we examined the 1000 most significantly changed acetylation peaks after ATRA induction in PML-RARα/RXR binding regions. The intensity plots covering the region of 10 kb up-and downstream for cells treated with ATRA and MC2392 show acetylation increases following MC2392 treatment although to a lower level and after longer treatment times as compared to ATRA (Fig. 2D ): a vivid increase is already apparent after 4h of ATRA treatment whereas a similar response amplitude is reach only after 48h of MC2392 treatment.
The normalized tag numbers (in treated and untreated samples) were counted for all binding regions and clustered using k-means. This analysis identified 20 clusters ( Supplementary Fig. 1B ), amongst which in particular cluster 2 and cluster 9 showed H3K9K14ac peaks that responded similarly to ATRA for 4h and 24h, and to MC2392 for 24h and 48h though with a strong timely delay (Fig. 3A) . Recent studies analyzing the genome-wide PML-RARα binding sites not only identified DR2 and DR5 elements as the primary PML-RARα response elements but also regions containing DR1, DR3 and DR4 motifs (33, 39) . We found that both the DR1 and DR2 motifs are enriched within the cluster 2 and 9 binding sites (Fig. 3B , middle) whereas DR3, DR4 and DR5 motifs are not enriched.
In addition, a de novo motif search identified the DR1 element in the 191 H3K9K14ac peaks of the cluster 2 that are regulated by MC2392 (Fig. 3B, bottom) . This suggest that a proper configuration, i.e. spatial position of the PML-RARα with respect to the HDAC(s) in the repressive complex is an important prerequisite for MC2392 to physically bridge the RAR and HDAC(s) moieties and consequently cause inhibition of HDAC activity.
MC2392, but not ATRA, induces H3K9K14 acetylation at pro-apoptotic genes.
Our analysis also revealed cluster 8 consisting of 774 regulated genes that showed an opposite epigenetic response to MC2392 as compared to ATRA treatment ( ChIP experiments coupled with qPCR showed enrichment of Nrf2 over specific responsive element (ARE) of target genes after MC2392 treatment, confirming an early Nrf2-mediated transcriptional response during oxidant-induced cell death, differently to ATRA which reduces the binding of Nrf2 to the ARE enhancer region ( Supplementary Fig. 1D ).
Finally, we found an increase in transcription in the target genes that encode antioxidant proteins or enzymes to buffer the intracellular redox activities, such as FTH1, GCLM, GCLC, NQO and HMOX, STK17A. Conversely, ATRA inhibits/reduces the expression of these Nrf2 target genes (Supplementary Fig. 2A ). To analyze the expression changes induced by MC2392, we performed transcriptome profiling on MC2392 and ATRA-treated NB4 cells. The gene expression values from RNA-seq data were calculated by quantifying the number of sequence tags for each genes using Genomatix (40, 41) .
Scatter plots show the general differences of gene expression of MC2392 versus ATRA after 24 and 48h ( Supplementary Fig. 2B ). Moreover, functional annotation clustering of differentially expressed genes by Gene Ontology (GO; PANTHER) analysis revealed that genes up-regulated in response to MC2392 are enriched for terms associated with protein transport, response to stress and apoptosis induction. Moreover ATRA up-regulated genes are enriched for terms associated mostly to protein transport and metabolic processes ( Supplementary Fig. 2C ). The hierarchical clustering analysis supports these data ( Supplementary Fig. 2D ).
Moreover, MC2392 down-regulated genes are enriched for terms associated with metabolic processes and pathway analysis showed the decreased expression of components that drive cell growth, proliferation and cell communication such as JAK/STAT and integrin pathway (data not shown).
Analysis of the transcription level of the 148 genes associated with apoptosis (http://www.reactome.org) revealed main differences between ATRA and MC2392 ( Supplementary   Fig. 2E and Supplementary Materials) such as the fast induction of TRAF2, E2F1, DYNLL2 and DBNL following MC2392 but not ATRA treatment. Next, we selected several MC2392-modulated genes related to apoptosis and oxidative stress, which are also modulated in the H3K914ac levels ( Fig. 3 and Supplementary Fig. 1 ) upon MC2392 but not ATRA treatment and examined transcription factor binding. This revealed an increased occupancy of c-Jun, c-Fos and NRF2 in a time-and MC2392-dependent manner ( Supplementary Fig. 3 ), corroborating and extending our observations that the apoptotic action of the MC2392 is causally bound to the modulation of cell death and redox pathways in response to modulation of AP1 and NRF2 bindings and 12 their downstream pathways. Taken together the transcriptome and histone H3 acetylome analysis strongly point to a differential effect of MC2392 as opposed to ATRA on apoptotic genes.
MC2392 induces cell death in APL cells.
Genome-wide epigenetic and transcriptome analysis have provided strong indications that MC2392 effects are distinct from those elicited by ATRA in particular on apoptotic genes. Therefore, we assessed the activity of MC2392 on NB4 proliferation, cell cycle progression, granulocytic differentiation and apoptosis induction in comparison to MS-275, SAHA, and ATRA (Fig. 4) .
Interestingly, analysis of NB4 clonogenicity in semisolid media upon MC2392 treatment ( MC2678, and MC2677, respectively) (42) were used. The MC2678 and -2677 compounds do not display HDAC inhibition (data not shown) and MC2677 has been previously described to inhibit the growth of a number of tumor cell lines including prostate, head and neck, squamous carcinoma and neuroblastoma (42, 43) . In contrast to MC2392 and MS-275, MC2678 and MC2677 are unable to induce a proliferation arrest of NB4 cells (Fig. 4A, right) . MC2392 increased the pre-G1 fraction (Fig. 4B) , a measure of cell death induction but did not induce major changes in the cell cycle phases (Fig. 4C ). MC2392 did also induce an increase of the CD11c levels to 24%, thus inducing maturation of APL cells similar to ATRA, MC2677 and MC2678 (Fig. 4D) but the MC2678 and MC2677 compounds did not induce apoptosis (Fig. 4B ).
Induction of cell death by MC2392 is not dependent on differentiation as MC2392 readily induces cell death but not differentiation of the ATRA-resistant NB4 subclone, NB4R4 (26, 27) (Fig. 4E-F) .
Note that as a result of the acquired mutation in the ligand-binding domain, PML-RARα can bind ATRA but it is thought that the binding does not induce the conformational change needed to dissociate the repressive complex and recruit activating proteins (26) . Thus, the cell death activity of MC2392 acts independently from maturation and is likely linked to the HDAC inhibition of the 
MC2392-induced cell death involves ROS and caspase-8.
To gain insight into the mechanism(s) by which MC2392 initiates cell death, caspases-8, -9 and -3/7 activities in NB4 cells were analyzed. Similarly to SAHA, MC2392 notably induced caspase activation with caspase-8, -9 (initiator caspases), caspase-3/7 (effector caspases) (Fig. 5A-B ) and mitochondrial potential activated in NB4 cells (Fig. 5C ), thus indicating that the cell death induced by MC2392 is caspase dependent. MS-275 induced cell death is caspase-8 dependent and related to TRAIL induction (22) . In order to identify the molecular pathway we evaluated the levels of known players of apoptosis, such as FAS, TRAIL, FADD, caspase-8 and -3/7, Bcl2 and Bid in NB4 cells after 24h and 48h treatment. As shown in Fig. 5D and Supplementary Fig. 3A , MC2392 induced the extrinsic apoptotic pathway, increased the expression of FasL, Fas and TRAIL similarly to what has been reported for MS-275 (22) . MC2392 also induced degradation of Bid into the apoptotic factor tBid, mitochondrial depolarization (Fig. 5D ) and Bcl2 down-regulation ( Supplementary Fig. 4B ).
Next, NB4 cells were treated with MC2392 and H 2 O 2 with and without the antioxidant Nacetylcysteine (NAC). The data suggest that MC2392 mediates a ROS-dependent cell death associated with the generation of reactive oxygen species (Fig. 5E and 5F ). We further observed increased H2AX phosphorylation which is a hallmark of ongoing DNA damage as a result of increased reactive oxygen species (ROS) (44, 45) . The response of APL cells to MC2392 includes the generation of ROS as a consequence of Bid cleavage, which triggers mitochondrial membrane permeabilization. As both caspase-2 and caspase-8 are capable of cleaving the pro-apoptotic Bid we set out to investigate whether caspase-2 or caspase-8 are responsible. MC2392 induced caspase-2 14 activation, which is fully blocked by the caspase-2 inhibitor Z-VDVAD-FMK (Fig. 6A) . However, cell death mediated by MC2392 stayed unaltered (Fig. 6A, right) . MC2392-mediated cell death is also not NOX-dependent, given that Apocynin -a NOX specific inhibitor -is not able to block apoptosis ( Supplementary Fig. 3C ). Furthermore, NF-kB is neither induced nor transcriptionally activated by MC2392 ( Supplementary Fig. 4D-4E) . In contrast, when the pan-caspase inhibitor ZVAD (data not shown) or the caspase-8 inhibitor IETD are used together with MC2392, NB4 cell death is fully abolished (Fig. 6B) , strongly suggesting that the MC2392 mechanism of cell death is caspase 8-dependent. Surprisingly, necrostatin-1 (NEC-1), the known RIP1 kinase and necroptosis inhibitor, completely abrogated MC2392 cell death (Fig. 6C ), thus suggesting a RIP1 mediated cell death. Consistent with these observations, analysis for RIPK1 expression showed both a strong upregulation upon MC2392 and a full abrogation with NEC-1 (Fig. 6D) . Finally, in line with our hypothesis, MC2392 induces cell death specifically in a PML-RARα but not in RARα or PML driven way (Fig. 4F and data not shown) .
Taken together our data revealed that at the level of acetylation, MC2392 induces much fewer changes as compared to ATRA. Moreover, MS-275 resulted in genome wide dampening and broadening of all acetylation sites ( Fig. 2A) whereas MC2392 affected acetylation only at a subset of PML-RARα sites (DR1-2 type). Finally, transcriptome analysis corroborated and extended that MC2392 affects apoptotic genes.
Discussion
Epigenetic modifications can be reversed by epi-drugs that are promising for antitumor therapy. In 
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specifically inhibits the HDACs contained in the PML-RARα repressive complex (Fig. 1D ). (Fig. 1E) and differentiation of NB4 cells (Fig. 4D) .
MC2392 induces degradation of PML-RARα
Genome-wide epigenetic analysis shows that MC2392 induces increased acetylation at a small subset of PML-RARα sites with preponderance for DR1 and -2 type (Fig. 3B) The fact that MC2392 may represent the first RARα-driven HDACi is corroborated by i) its inactivity on human recombinant HDACs in vitro, ii) its inability to modify general histone and/or tubulin acetylation; iii) its selective HDACi action on PML-RARα complexes; iv) its enhanced ability to induce apoptosis in APL cells but not in other leukemia or solid cancer models. The fact that MC2392 induces apoptosis in NB4 cells and increases caspases-8, -2 and -9 activity suggests that MC2392 activate both mitochondrial and death receptor apoptotic pathways. Although MC2392 is able to activate the extrinsic pathway by inducing FAS and TRAIL, the death response to MC2392 includes also the generation of ROS as a possible consequence of the cleavage of Bid (Fig. 5D, F) Fig. 2A ) and apoptotic genes (see Supplementary Materials and Methods). Finally, the evidence that apoptosis occurs in APL independently from an 'classical' ATRA response is suggested both by the MC2392 action in Zn-inducible PLZF-RARα expression in U937 cells (28, 29) as well as by its activity on NB4R4 cells (26, 27) . Note that in both PLZF-RARα U937 cells and in NB4R4 cells ATRA signaling stays impaired upon treatment (27, 46, 47) . Excitingly, given that MC2392 is not an HDACi in vitro, MC2392 is able to exert its HDAC inhibition only when driven by its ATRA moiety to PML-RARα and thereby co-localized to HDAC-containing repressive complexes (Fig. 4) . In this way, MC2392 relieves the HDAC repressive complex and allows induction of cell death in ATRA responsive and in bona fide APL ATRA-resistant cells. Accordingly, MC2392 is not inducing apoptosis in solid tumor such as prostate or breast cancer (data not shown). Moreover, ChIP-seq profiles show that MC2392 induces changes in H3 acetylation at a small subset of PML-RARα/RXR binding regions but also in regions not regulated by ATRA (Fig. 2, 3) . Unlike natural retinoids, MC2392 exerts distinct biological effects, inducing partial differentiation and promoting apoptosis, possibly similarly to As2O3. MC2392 displays a minimal or no cytotoxicity in other kind of tumor cells.
Collectively these data underpin the specificity and selectivity of the MC2392. In conclusion, MC2392 represents the creation of a single chemical entity with dual action thus reflecting the concept of a laboratory-created ad hoc drug, which as a single drug can overcome resistance in cancer. 
